JD Vance Predicts: Wall Street vs. Trump & Your Money

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Frederick Muto Biography and Net Worth

Director of Ionis Pharmaceuticals

Mr. Muto has served as a director of Ionis since March 2001. Mr. Muto joined the law firm of Cooley LLP, outside counsel to Ionis, in 1980, became a partner in 1986 and Senior Counsel in 2018. He is a founding Senior Counsel of Cooley LLP’s San Diego office and was Chair of the firm’s Business Department for a number of years.

What is Frederick T. Muto's net worth?: The estimated net worth of Frederick T. Muto is at least $1.30 million as of June 15th, 2021. Mr. Muto owns 36,683 shares of Ionis Pharmaceuticals stock worth more than $1,298,578 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Muto may own. Learn More about Frederick T. Muto's net worth.
How do I contact Frederick T. Muto?: The corporate mailing address for Mr. Muto and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Frederick T. Muto's contact information.
Has Frederick T. Muto been buying or selling shares of Ionis Pharmaceuticals?: Frederick T. Muto has not been actively trading shares of Ionis Pharmaceuticals during the last quarter. Most recently, Frederick T. Muto sold 15,000 shares of the business's stock in a transaction on Tuesday, June 15th. The shares were sold at an average price of $36.63, for a transaction totalling $549,450.00. Following the completion of the sale, the director now directly owns 36,683 shares of the company's stock, valued at $1,343,698.29. Learn More on Frederick T. Muto's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, insiders at the sold shares 25 times. They sold a total of 270,830 shares worth more than $13,480,539.63. The most recent insider tranaction occured on November, 12th when EVP Eric Swayze sold 1,194 shares worth more than $45,276.48. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 11/12/2024.

Frederick T. Muto Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/15/2021	Sell	15,000	$36.63	$549,450.00	36,683
6/4/2019	Sell	15,000	$65.29	$979,350.00	24,794
5/6/2019	Sell	8,000	$72.75	$582,000.00	17,794
5/31/2018	Sell	15,000	$46.45	$696,750.00	22,127
5/31/2016	Sell	12,500	$22.31	$278,875.00	15,043
6/2/2014	Sell	10,000	$28.59	$285,900.00
5/30/2013	Sell	10,000	$21.96	$219,600.00

Frederick T. Muto Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $35.40

$33.53

$35.60

50 Day Range

MA: $39.01

$33.73

$42.76

2 Week Range

Now: $35.40

$33.33

$54.44

Volume

2,223,243 shs

Average Volume

1,168,921 shs

Market Capitalization

$5.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39